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Uterine serous papillary carcinoma is a highly aggressive variant of endometrial cancer histologically similar to high grade
ovarian cancer. Unlike ovarian cancer, however, it is a chemoresistant disease from onset, with responses to combined
cisplatinum-based chemotherapy in the order of 20% and an extremely poor prognosis. In this study, we demonstrate that
tumour lysate-pulsed autologous dendritic cells can elicit a speciﬁc CD8
+ cytotoxic T lymphocyte response against autologous
tumour target cells in three patients with uterine serous papillary cancer. CTL from patients 1 and 2 expressed strong cytolytic
activity against autologous tumour cells, did not lyse autologous lymphoblasts or autologous EBV-transformed cell lines, and
were variably cytotoxic against the NK-sensitive cell line K-562. Patient 3 CD8
+ T cells expressed a modest but reproducible
cytotoxicity against autologous tumour cells only at the time of the ﬁrst priming. Further priming attempts with PBL collected
from patient 3 after tumour progression in the lumboaortic lymph nodes were unsuccesful. Cytotoxicity against autologous
tumour cells could be signiﬁcantly inhibited by anti-HLA class I (W6/32) and anti-LFA-1 MAbs. Highly cytotoxic CD8
+ T cells
from patients 1 and 2 showed a heterogeneous CD56 expression while CD56 was not expressed by non-cytotoxic CD8
+ T
cells from patient 3. Using two colour ﬂow cytometric analysis of intracellular cytokine expression at the single cell level, a
striking dominance of IFN-g expressors was detectable in CTL populations of patients 1 and 2 while in patient 3 a dominant
population of CD8
+ T cells expressing IL-4 and IL-10 was consistently detected. Taken together, these data demonstrate that
tumour lysate-pulsed DC can be an effective tool in inducing uterine serous papillary cancer-speciﬁc CD8
+ CTL able to kill
autologous tumour cells in vitro. However, high levels of tumour speciﬁc tolerance in some patients may impose a signiﬁcant
barrier to therapeutic vaccination. These results may have important implications for the treatment in the adjuvant setting of
uterine serous papillary cancer patients with active or adoptive immunotherapy.
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Uterine serous papillary carcinoma (USPC) is a histologic subtype
of endometrial cancer constituting up to 10% of all endometrial
cancers. Histologically similar to high grade ovarian cancer
(Carcangiu and Chambers, 1992; Sherman et al, 1992), USPC has
a propensity for early intra-abdominal and lymphatic spread even
at presentation (Carcangiu and Chambers, 1995; Goff et al, 1994)
and is characterized by a highly aggressive biologic behaviour
(Carcangiu and Chambers, 1992; Goff et al, 1994; Sherman et al,
1992). In contrast to ovarian cancer, however, it is a chemoresis-
tant disease from onset with responses to combined cisplatinum-
based chemotherapy in the order of 20% (Levenback et al, 1992;
Nicklin and Copeland, 1996). The survival rate is dismal, even
when USPC is only a component of the histologically more
common endometrioid adenocarcinoma (Carcangiu and Cham-
bers, 1992, 1995). The overall 5-year survival is 30+9% for all
stages and the recurrence rate after surgery is extremely high
(50–80%). Novel therapeutic strategies and a deeper molecular
understanding of host interactions with possible carcinogenic
factors are desperately needed.
To date, with the exception of melanoma (Castelli et al, 1996;
Cox et al, 1994), there is limited information on the intrinsic
immunogenicity or the identity and density of antigenic peptides
and CTL epitopes presented by the majority of spontaneously
arising human tumours. However, in the last few years several
reports have shown that multiple epitopes can be recognized by
T cells on several human tumours (i.e. ovarian, pancreatic, breast
and lung) (Joannides et al, 1993; Peoples et al, 1995; Yoshino et
al, 1994). Therefore, an alternative strategy for effective vaccina-
tion of tumour patients may be the use of unfractionated
tumour-derived antigens such as whole tumour cells, peptides
or proteins isolated from tumour cells. In this regard, effective
tumour immunity in several murine tumour models has been
induced using professional antigen presenting cells (pAPC) such
as dendritic cells (DC) pulsed with unfractionated tumour-derived
antigens in the form of peptides (Nair et al, 1997a; Zitvogel et al,
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(mRNA) (Boczkowski et al, 1996).
Studies performed by several groups including our own have
recently established the key role played by dendritic cells (DC) in
the immune system and provide a rationale for using DC as natur-
al adjuvants for human immunotherapy (Santin et al, 1999a;
Steinman, 1991; Young and Inaba, 1996). DCs are the most effec-
tive APC at activating naive T cells (Steinman, 1991; Young and
Inaba, 1996), and recently the combination of GM-CSF and IL-4
has been shown to generate large numbers of DCs from peripheral
blood monocyte precursors (Romani et al, 1994; Sallusto and
Lanzavecchia, 1994). In this study, we have used autologous DCs
pulsed with USPC lysate to induce a tumour-speciﬁc T cell
response from three USPC patients. Here, using a completely auto-
logous system, we report the in vitro induction of HLA class I-
restricted CD8
+ CTLs in patients with advanced USPC. In addi-
tion, using two colour ﬂow cytometric analysis of intracellular
cytokine expression at the single cell level, we show that a strongly
polarized Type 1 pattern of cytokine expression was inducible in
the tumour antigen-primed CD8
+ T cells of two patients, and that
this phenotype correlated with high cytotoxic activity. In contrast,
tumour antigen-primed CD8
+ T cells from patient 3 showed mini-
mal tumour-speciﬁc cytotoxicity, and exhibited a strong Type 2
bias in cytokine expression. These results may have important
implications for treatment with active or adoptive immunotherapy
of chemotherapy and radiotherapy resistant USPC.
MATERIALS AND METHODS
Patients
Three patients who had undergone total abdominal hysterectomy
and regional lymph node sampling for invasive USPC provided
tumour tissue and peripheral blood mononuclear cells (PBMC).
Specimens were obtained at the time of surgery through the Gyne-
cologic Oncology Department and the Pathology Department of
the University of Arkansas for Medical Sciences (UAMS), Little
Rock, Arkansas, under approval of the Institutional Review Board.
Patient 1 had stage IIIA endometrial cancer and was aged 34 years,
while patients 2 and 3 had stage IIIC adenocarcinoma and were
aged 52 and 53 years, respectively. Patients did not receive any
form of therapy prior to surgery.
Tumour cell lines
The natural killer (NK) sensitive target K562 (a human erythro-
leukaemia cell line) was purchased from American Type Culture
Collection and was maintained at 378C, 5% CO2 in complete
medium (CM) containing RPMI 1640 (Gibco-BRL, Grand Island,
NY, USA), 10% foetal bovine serum (FBS, Gemini Bioproducts,
Calabasas, CA, USA). Fresh autologous tumour samples were
obtained from surgical specimens from all patients and were
reduced to single cell suspensions under sterile conditions at
room temperature, as previously described (Santin et al, 1996).
Fresh tumour cell lines were maintained initially in RPMI
1640, supplemented with 15% autologous ascites ﬂuid, and
thereafter when established with 10% FBS at 378C, 5% CO2.
Brieﬂy, single cell suspensions were obtained by processing solid
tumour samples under sterile conditions at room temperature.
Viable tumour tissue was mechanically minced in RPMI 1640
to portions no larger than 1–3 mm
3 and washed twice with
RPMI 1640. The portions of minced tumour were then placed
into 250 ml trypsinizing ﬂasks containing 30 ml of enzyme solu-
tion (0.14% Collagenase Type I (Sigma, St. Louis, MO, USA)
and 0.01% DNAse (Sigma, 2000 KU mg
71)) in RPMI 1640,
and incubated on a magnetic stirring apparatus overnight at
48C. Enzymatically dissociated tumour was then ﬁltered through
150 mm nylon mesh to generate a single cell suspension. The
resultant cell suspension was then washed twice in RPMI 1640
plus 15% autologous ascites and thereafter seeded in T-75 or
T-150 tissue cultures ﬂasks (Corning, Costar Corp., Cambridge,
MA, USA). The percentage of tumour cells used for tumour
lysate applied to the DC or used as target cells in cytotoxicity
assays (see below) was determined by cytokeratin expression
using immunohistochemical techniques. All cell lines evaluated
contained 499% tumour cells.
HLA phenotypic analysis of CD8
+ cultures
HLA class I typing of puriﬁed CD8
+ cultures was performed by
standard lymphocytotoxicity tests (Hopkins, 1990) in the tissue
typing laboratory of the bone marrow transplantation and blood
transfusion service at UAMS.
Preparation of tumour lysate
5–10610
6 autologous tumour cells cultured in RPMI 1640 15%
autologous ascites were washed twice with phosphate-buffered
saline (PBS, pH 7.4) and harvested by scraping. Cells were lysed
by three to four freeze cycles (in liquid nitrogen) and thaw cycles
(room temperature). Lysis was monitored by light microscopy.
Larger particles were removed by centrifugation (10 min, 400 g),
supernatants were passed through a 0.2-mm ﬁlter, and stored at
7808C until use.
Isolation of PBMC and generation of dendritic cells
PBMCs were separated from heparinized venous blood by Ficoll-
Hypaque (Sigma) density gradient centrifugation and either cryo-
preserved in RPMI 1640 (Gibco-BRL) plus 10% DMSO and 30%
autologous plasma, or immediately used for DC generation.
Brieﬂy, PBMC obtained from 42 ml of peripheral blood were
placed into 6-well culture plates (Costar, Cambridge, MA,
USA) in AIM-V medium (Gibco-BRL) at 0.5-1610
7/3 ml per
well. After 2 h at 378C, nonadherent cells were removed, and
the adherent cells were cultured at 378C in a humidiﬁed 5%
CO2/95% air incubator, in medium supplemented with recombi-
nant human GM-CSF ((800 U ml
71), Immunex, Seattle, WA,
USA) and IL-4 ((1000 U ml
71) Genzyme, Cambridge, MA,
USA) (Romani et al, 1994). Every 2 days, 1 ml of spent medium
was replaced by 1.5 ml of fresh medium containing 1600 U ml
71
GM-CSF and 1000 U ml
71 IL-4, to yield ﬁnal concentrations of
800 U ml
71 and 500 U ml
71, respectively (Romani et al, 1994).
After 6 or 7 days of culture, DC were harvested for pulsing with
tumour lysate as described below. The DC purity (i.e. cells
strongly expressing HLA-DR
+, CD86
+, CD40
+, and CD14
-)
ranged from 58 to 86% of the total cell population with a mean
of 69+12%, as previously characterized by our laboratory
(Santin et al, 1999b). No signiﬁcant differences were noted in
the expression of HLA-DR or costimulatory molecules (i.e.,
CD86, CD40), among DC cultures derived from the three
patients (data not shown).
DC pulsing
Following culture, DC were washed twice in AIM-V and added to
50 ml polypropylene tubes (Falcon, Oxnard, CA, USA). The catio-
nic lipid DOTAP (Boehringer Mannheim, Indianapolis, IN, USA)
was used to deliver the total cell extract into cells. Five hundred
microlitres of total cell extract derived from 5–10610
6 tumour
cells in AIM-V and DOTAP (125 mg in 500 ml of AIM-V) were
mixed in 12675 mm polystyrene tubes at room temperature for
20 min. The complex was added to the DC in a total volume of
2–5 ml of AIM-V and incubated at 378C with occasional agitation
for 3 h. The cells were washed twice with PBS and resuspended in
AIM-V as described below.
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Fresh or cryopreserved responder PBMC were washed and resus-
pended in AIM-V at 10–20610
6 cells per well in 6-well culture
plates (Costar) with tumour lysate-pulsed autologous DC (ratios
from 20:1 to 30:1 responder PBMC: DC). The cultures were
supplemented with recombinant human GM-CSF (500 U ml
71)
and recombinant human IL-2 (10 U ml
71 Aldesleukin, Chiron
Therapeutics, Emeryville, CA, USA) and incubated at 378C.
Human rIL-2 (10 U ml
71) was added to the cultures thereafter
every 3-4 days. At day 21, CD8
+ cells were separated from the bulk
cultures by positive selection with CD8-Dynabeads (Dynal Inc.,
Lake Success, NY, USA) and further expanded in number for 7–
10 days using autologous or allogeneic irradiated PBL (5000 cGy)
(1610
6 cells per well) as feeder cells and anti-CD3 monoclonal
antibody (Ortho Pharmaceutical Corp, Raritan, NJ, USA)
(0.2 mgm l
71) plus 5% autologous plasma in 24-well plates (Cost-
ar) before being assayed for CTL activity. As negative control
targets, autologous lymphoblasts were prepared by 3-day stimula-
tion with Con-A (Gibco-BRL; 1 mgm l
71) in RPMI-1640 plus IL-
2 (25 U ml
71), while EBV-transformed autologous lymphoblastoid
B-cell lines (LCL) were established by coculture of PBMCs with
EBV-containing supernatant from the B95.8 cell line in the
presence of 1 mgm l
71 cyclosporin A (Sandoz, Camberley, UK)
and were maintained in RPMI supplemented with 10% human
AB serum (Gemini Bioproducts).
Cytotoxic activity
A 6-h chromium (
51Cr) release assay was performed as previously
described (Nazaruk et al, 1998) to measure the cytotoxic reactivity
of DC-tumour lysate stimulated CD8
+ T lymphocytes. In addition
to autologous tumour cells, K562 cells were used as a target for the
detection of NK activity. Con-A activated peripheral blood
lymphocytes and/or EBV-transformed LCL were used as autolo-
gous control targets. To determine the structures on the effector
and target cells involved in lysis, monoclonal antibodies (MAbs)
were used to block cytotoxicity. Effector cells were preincubated
for 30 min at room temperature with MAbs which recognize
human anti-CD11a/LFA-1 (10 mgm l
71) (PharMingen, San Diego,
CA, USA) and its isotype control (IgG1k mAb isotype standard
anti-TNP (10 mgm l
71) (PharMingen)).
51Cr-labelled tumour
targets were preincubated with MAbs speciﬁc for monomorphic
HLA class I (W6/32) (50 mgm l
71). The effector cells and
51Cr-
labeled targets were then incubated in a ﬁnal volume of 200 ml
per microwell at 378C with 6% CO2.
Phenotypic analysis of T cells and autologous tumour cells
Enriched cultures of CD8
+ T cells were phenotyped at the time of
the ﬁrst cytotoxicity assay and thereafter in order to correlate cyto-
lytic speciﬁcity with a particular lymphoid subset. Flow cytometry
was performed using MAbs directly conjugated against the follow-
ing human leukocyte antigens: Leu-4 (CD3, pan T cells); Leu-3
(CD4, T helper/inducer); Leu-2a (CD8, T cytotoxic/suppressor);
Leu-19 (CD56, NK/K cells); anti-CD16; Tac (CD25, the IL-2R);
anti-HLA-DR (L-243); anti TcR-a/b or TcR-g/d (all Becton Dick-
inson, San Jose, CA, USA) and analyzed on a FACScan (Becton
Dickinson). Autologous tumour cells were analyzed for MHC class
I expression as previously described (Santin et al, 1996). Brieﬂy,
tumour cells were harvested with 0.25% Trypsin in HBS (Gibco-
BRL) and washed once in CM. Cell suspensions were counted
and distributed into 12675 mm tubes at 5610
5 cells per tube.
Mouse monoclonal antibodies were diluted in cold assay buffer
(PBS, pH 7.2, supplemented with 0.1% FCS) and added in a 50-
ml volume. A mouse IgG preparation (mAb IgG2a; Becton Dickin-
son) was used as negative control. Analysis was conducted with
FACScan utilizing Cell Quest software (Becton Dickinson).
Flow cytometric analysis of intracellular cytokines
This protocol is adapted from that described by Openshaw et al.
(1995). Flow cytometric analysis of intracellular cytokine expres-
sion was conducted essentially as previously described (Santin et
al, 1999a). CD8
+ T cells were tested at about 6 weeks after prim-
ing, after resting for 14 days after last antigen stimulation.
Brieﬂy, T cells (7.5610
5 ml
71) were incubated at 378C for 6 h
in AIM-V 5% autologous plasma plus 50 ng ml
71 PMA and
500 ng ml
71 ionomycin. Ten mgm l
71 Brefeldin A was added
for the ﬁnal 3 h of incubation. Controls, (non-activated cultures)
were incubated in the presence of Brefeldin A only. The cells
were harvested, washed and ﬁxed with 2% paraformaldehyde in
PBS for 20 min at room temperature, after which they were
washed and stored overnight in PBS at 48C. For intracellular
staining, the cells were washed and permeabilized by incubation
in PBS plus 1% BSA and 0.5% saponin (S-7900, Sigma) for
10 min at room temperature. Activated and control cells were
stained with FITC-anti-IFN-g, and PE-anti-IL-4, and isotype-
matched controls (FITC-anti-Igg2a and PE-anti-Igg1) from
Becton-Dickinson. After staining, cells were washed twice with
PBS plus 1% BSA and 0.5% saponin, once with PBS plus
0.5% BSA, and ﬁxed a second time with 2% paraformaldehyde
in PBS. Analysis was conducted with a FACScan utilizing Cell
Quest software (Becton Dickinson).
RESULTS
HLA typing
The peripheral blood mononuclear cells from the USPC patients
manifested the following haplotypes: PT 1; HLA A24, A66, B7,
B44, Cw7, Cw16, Bw4, Bw6. PT 2; HLA A3, A23, B51, B58,
Cw6, Cw5, Bw4. PT 3; HLA A23, B49, Cw7, Bw4.
HLA class I expression by autologous tumour cells
MHC class I expression was evaluated by FACS analysis on the
tumour cell lines established from all three patients. As can be seen
in Figure 1, all tumour cell lines expressed MHC class I molecules.
In addition, IFN-g exposure was able to induce a signiﬁcant upre-
gulation of HLA class I expression in all three cell lines (data not
shown).
Tumour-speciﬁc CD8
+ cytotoxic T cell responses
Cytotoxicity assays were conducted with puriﬁed CD8
+ T cells at
a minimum of 4 weeks after stimulation of T cell cultures with
tumour lysate-pulsed DC. Results are presented as the mean
values from at least three independently primed CD8
+ T cell
cultures from each patient. As shown in Figure 2, cytotoxicity
against autologous tumour cells was demonstrated for patients 1
and 2, at an effector:target ratio 20:1. For these patients, tumour
speciﬁc cytotoxicity was signiﬁcantly inhibited by blocking MAb
against HLA class I (signiﬁcant at P50.001 for patient 1, and
P50.05 for patient 2, Student’s matched-pairs t-test). Lysis of
NK-sensitive K562 cells was also observed, notably for the CD8
+
T cells from patient 1. However, lysis of autologous tumour cells
was signiﬁcantly higher than lysis of K-562 cells (P50.05 for both
patients 1 and 2). Collectively, these results suggest that speciﬁc,
HLA class I-restricted cytotoxicity against autologous tumour
antigens is a major component of the CD8
+ T cell response
following stimulation with tumour lysate-pulsed DC, although
an NK-like CD8
+ cytotoxic T cell response is also detected from
patient 1. In patient 2, we also show that anti-CD11a (LFA-1)
MAb were able to block tumour lysis, the range of inhibition
being from 50 to 65% (Figure 2). This observation suggests that
the CD11a-CD54 adhesion pathway may play an important role
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+ T cell lysis of USPC target cells. In contrast to
the cytotoxic responses generated from patients 1 and 2, we were
able to generate only a very low level of T cell mediated cytotoxi-
city from a single DC-primed CD8
+ T cell culture from patient 3
(Figure 2). Two further attempts at priming tumour-speciﬁc
CD8
+ cytotoxic T cell responses from patient 3 were unsuccessful.
For all three patients, minimal levels of cytotoxicity against auto-
logous Con A-stimulated lymphoblasts (data not shown) or EBV-
transformed LCL were observed.
Phenotypic analysis of CD8
+ T cells
Flow cytometric analysis was used to determine the phenotype of
the populations of tumour-stimulated CD8
+ T-cells derived from
the three patients. All the cells were CD3/CD8
+ and CD4
7, with
a variable proportion of CD56-antigen positive cells. CD8
+ T cells
were also TCR-ab+ (94–98%), TCR-gd+ (2–5%), CD25+, HLA-
DR+ and CD167 (data not shown). Co-expression of CD56 on
CD8
+ T lymphocytes was further analyzed by two colour immuno-
ﬂuorescence (Figure 3). CD8
+ T lymphocytes from patients 1 and
2, but not patient 3 (Figure 3), co-expressed the CD56 surface anti-
gen during culture (range from 15 to 52%).
Intracellular cytokine expression by tumour-speciﬁc T cells
To evaluate whether cytokine expression from tumour-stimulated
CD8
+ T cells segregated in discrete IFN-g+/IL-47 and IFN-g-/IL-
4+ subsets we took advantage of recently developed ﬂow cytometric
techniques for the detection of intracellular cytokine expression at the
single cell level. Two colour ﬂow cytometric analysis of intracellular
IFN-g and IL-4 expression by CTLs was performed after 6 weeks of
culture. As shown in Figure 4, a large majority of CD8
+ T cells from
patients 1 and 2 expressed intracellular IFN-g but not IL-4. In
contrast, CD8
+ T cells from patient 3 showed a striking dominance
of IL-4 expressors (Figure 4) and less than 1% expressed IFN-g. Simi-
lar results were obtained in several repetitive analyses for all patients.
Unactivated (i.e. resting) CD8
+ T cells from all three patients failed to
stain for IFN-g or IL-4. Similarly, FITC-anti-IgG2a and PE-anti-IgG1
isotype controls did not stain either activated or unactivated CD8
+ T
cells (data not shown).
DISCUSSION
Tumour-speciﬁc CTLs recognizing multiple epitopes on a variety
of epithelial tumours have recently been generated in vitro from
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Figure 1 Expression of MHC Class I molecules on USPC cells. Surface
antigen expression was measured by FACS as described under Materials
and methods. A representative experiment is shown. Open proﬁle: isotype
control; solid proﬁle: anti-MHC class I MAbs.
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Figure 2 Tumour speciﬁc CD8
+ CTL responses induced by tumour
peptide-pulsed DCs in patients with USPC, measured in a 6 h
51Cr-release
assay. Percentage lysis (+ standard deviation) at a 20:1 effector/target cell
ratio is shown. Anti-HLA class I blocking antibody (W6/32) was used at
50 mgm l
71 while anti-CD11a/LFA-1 was used at 10 mgm l
71. Patient 1;
1, Autologous tumour; 2, Autologous tumour+W6/32 anti-HLA class I
MAb; 3, LCL control; 4, K562. Patient 2; 1, Autologous tumour; 2, Autolo-
gous tumour+W6/32 anti-class I MAb; 3, Autologous tumour+anti-LFA-1
MAb; 4, LCL control; 5, K562. Patient 3; 1, Autologous tumour; 2, Autolo-
gous tumour+W6/32 anti-HLA Class I MAb; 3, LCL control; 4, K562. Va-
lues are presented as the mean of at least three independently primed T
cell cultures.
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Peoples et al, 1995; Yoshino et al, 1994). Unfortunately, the possi-
ble immunization of cancer patients using deﬁned tumour antigens
is limited at present to a handful of human tumour types in which
candidates for tumour rejection antigens have been identiﬁed. In
an attempt to overcome these major limitations, several investiga-
tors have recently reported induction of effective tumour immunity
using DCs pulsed with unfractionated tumour-derived materials,
acid eluted peptides or messenger RNA (mRNA) (Boczkowski et
al, 1996; Nair et al, 1997a,b; Zitvogel et al, 1996). Hence, DC
vaccine treatment might be extended to patients with a variety of
solid tumours, provided that in vitro conﬁrmation of tumour-
speciﬁc CTL activity has been achieved.
In this study, we show that strong CD8
+ cytotoxic T cell
responses against autologous tumour cells can be induced in USPC
patients following stimulation of PBL with tumour lysate-pulsed
DC. Although CD8
+ cytotoxic T cells stimulated in this fashion
showed some lytic activity against NK-sensitive K562 cells, much
higher levels of cytotoxicity against autologous tumour cells were
observed from patients 1 and 2. Furthermore, tumour-speciﬁc
cytotoxicity was signiﬁcantly inhibited by blocking MAb speciﬁc
for HLA class I, indicating that a classical HLA-restricted CD8
+
cytotoxic T cell response against tumour antigens was a major
component of the response. In addition, CD16, a hallmark of
NK cells, was not expressed by DC-stimulated CD8
+ T cells.
Phenotypic analysis revealed a signiﬁcant CD56
+ subpopulation
within the CD8
+ CTL from patients 1 and 2, but not from patient
3. This is in agreement with our previous results on CD8
+ CTL
populations stimulated by HPV16/18 full length E7-pulsed DC in
cervical cancer patients (Santin et al, 1999a), as well as the results
of others (Hilders et al, 1994; Pittet et al, 2000), where CD56
expression by CD8
+ CTL was shown to correlate with cytotoxic
activity against autologous tumour cells. In addition, the highest
level of CD56 expression was observed with the CD8
+ CTL from
patient 2, which showed anti-HLA class I-blockable tumour lysis,
but negligible killing of K562 or other control targets. From these
observations, we conclude that CD56 expression by CD8
+ CTL
does not correlate with NK activity. Autologous LCL or Con-A
activated blasts were not killed by tumour speciﬁc CTLs, indicating
that while these CTLs were highly cytolytic for autologous tumour
cells, they failed to kill autologous normal cells.
T cell-mediated protection from viral infection as well as control
of tumours is thought to be promoted by Type 1 cytokine
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Figure 3 Two-colour ﬂow cytometric analysis of CD56 expression by
ovarian tumour-speciﬁc CD8
+ T cells. T cells were phenotyped at the time
of ﬁrst cytotoxicity and thereafter as described in the Materials and
methods. A representative experiment for each patient is shown. (A, B
and C) Patients 1, 2 and 3, respectively.
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Figure 4 Two-colour ﬂow cytometric analysis of intracellular IFN-g and
IL-4 expression by tumour speciﬁc CD8
+ T cells. T cells were tested at
about 6 weeks after priming, after resting for 14 days after the last antigen
stimulation prior to activation by PMA and ionomycin. (A, B and C)
Patients 1, 2 and 3, respectively. A representative experiment for each pa-
tient is shown.
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see Romagnani, 1992). In general, Type 1 T cells (CD4 or CD8)
express IL-2, IFN-g, and TNFa/b, and are cytotoxic, whereas Type
2 T cells express IL-4, IL-5, IL-6, IL-10 and IL13, provide efﬁcient
help for B cell activation, and are non-cytotoxic. Consistent with
this view, recent studies have showed signiﬁcant dysfunction of
Type 1 T cell responses in patients with cancer, suggesting that
progression of disease may be associated with a preferential Type
2 T cell response (Ghosh et al, 1995; Romagnani, 1992; Tsukui
et al, 1996). Selection of T cell phenotype at the time of the inter-
action with Ag-pulsed DC is known to be determined by a number
of factors including (1) the cytokine milieu at priming, with IL-12
favouring Type 1 and IL-4 favouring Type 2 responses, (2) the
nature and the intensity of TCR-mediated activation signals, (3)
the percentage of naive and primed T cells present at the time of
antigen exposure and (4) the costimulatory signals provided by
surface molecules expresssed on APC as well as their level of
expression (for review see Coffman et al, 1999). Two colour ﬂow
cytometric analysis of intracellular IFN-g and IL-4 expression by
CD8
+ T cells demonstrated that tumour-speciﬁc T cells from USPC
patients 1 and 2 showed a major Type 1 bias in cytokine expres-
sion. Indeed, a large majority of cytokine expressing T cells
showed IFN-g expression while a second minor subset contained
only IL-4 and a third subset contained both (Figure 4). Patient 3
showed a low but reproducible level of cytotoxicity, ranging from
6 to 13% from only the ﬁrst DC-primed CD8
+ T cells. Two succes-
sive attempts of priming conducted with PBMC obtained from the
patient at the time of histologically conﬁrmed gross tumour
progression in the lymphatic system (lumbo-aortic lymph nodes)
were unsuccessful. The reasons why tumour lysate pulsed DC
stimulated CD8
+ T cells from these primings from patient 3 were
not able to generate a cytotoxic response against autologous
tumour cells are open to speculation. However, it is notable that
a striking dominance of IL-4 over IFN-g expressing CD8
+ T cells
from patient 3 was reproducibly detected by ﬂow cytometry. We
consider it probable that a strong Type 2 bias in the CD8
+ T cell
response accounts for the lack of cytotoxic effector function from
this patient. Supporting this view, CD8
+ T cells isolated during
these ineffective primings secreted large amounts of IL-10 as
detected by ELISA when stimulated by solid phase OKT3 (data
not shown). A more difﬁcult question is why patient 3 should
respond in this manner. It is possible that the Type 2 bias in T cell
responses, which was also observed for CD4
+ T cells from patients
3 (not shown), may be related to the progressive nature of the
disease. At the time of the ﬁrst DC priming, which generated a
limited cytotoxic response, the patient had gross endometrial
disease, but limited metastatic spread, whereas later tumour
lysate-pulsed DC primings, which consistently induced non-cyto-
toxic Type 2 CD8
+ T cell responses, were attempted when the
tumour had heavily involved the regional pelvic and lumbo-aortic
lymph nodes. Extensive lymph node metastasis may thus be asso-
ciated with tumour speciﬁc tolerance (Santin, 2000).
Taken together, the ﬁndings of this study show that patients
harbouring locally advanced USPC with limited metastatic spread
to the secondary lymphoid organs can elicit a powerful cytotoxic
T cell response against their autologous tumour in vivo following
tumour lysate-pulsed-DC stimulation. However, evidence of
tumour speciﬁc tolerance in some patients may impose a signiﬁ-
cant barrier to DC-based immunotherapy. In this group of
patients, attempts to alter established Th2 responses with the use
of strongly polarizing Th1 agents such as IL-12, IFN-g, IFN-a,
anti-IL-4 and anti-IL-10 MAbs (Coffman et al, 1999) might there-
fore have considerable therapeutic implications.
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